DIRECTOR, USAMRAA, 820 CHANDLER ST, FORT DETRICK MD 21702-5014

65 -- HEMOSTATIC DRESSING SOL 074&&&-9902-0006 POC Cheryl Miles, Contract Specialist 301-619-7148, FAX 301-619-3166, e-mail cheryl.miles@amedd.army.mil (Site Code DAMD17) E-MAIL: cheryl.miles@amdd. k-ccmail.army.mil, cheryl.miles@amdd. k-ccmail.army.mil. Request for Information/Interest: The U.S. Army Medical Department (AMEDD) has established the Hemostatic Dressing (HD) development effort to obtain for military use a means to control potentially fatal hemorrhage. The HD, when applied using direct pressure, is intended to provide enhanced hemorrhage control in wounds with severe arterial, venous, and/or diffuse bleeding. A product to control minor or oozing hemorrhage is not being sought. The AMEDD is seeking manufacturers who are actively developing or marketing hemostatic agents. This is not a request for proposal. The intent is to solicit prototypes that will be examined under loan agreements. Technical Objectives of this program include, but are not limited to: 1. A HD that utilizes any combination of hemostatic materials composed of biologically compatible components that can be used for internal and external casualty sites. If human blood components are utilized, they must be treated to inactivate potential blood borne pathogens including viruses. 2. A HD that will develop a strong, durable clot at the bleeding site within two minutes or less when properly applied with appropriate pressure. 3. A HD that has no odor detectable by humans at a distance greater than ten feet from the soldier using the dressing. 4. A HD with a shelf life of three years or longer. 5. A HD that does not require refrigerated storage. 6. A HD that consists of dressing capable of being affixed to a wound. 7. A product that is capable of being packaged to permit survival in a field environment. The AMEDD will assess candidate product performance using three severe injury animal models: liver injury, crush injury and aortatomy. These studies will be conducted under Good Laboratory Practice protocols. Manufacturers must be willing to provide appropriate quantities of their product for the studies. Participating manufacturers will be given the results of how their product compared to the control gauze dressing. All interested companies should submit their name to the Contract Specialist via facsimile, letter, or e-mail NLT 24 Feb 99. Tentative schedule: Information packages will be distributed to interested parties by 26 Feb 99. Questions and pertinent comments must be submitted to the Contract Specialist NLT 8 Mar 99. The Notice of Intent to participate under a loan agreement must be submitted to the Contract Specialist by 15 Mar 99. Prototype delivery (up to 150 samples in 4''x 4'' dimensions or equivalent) would be required NLT 15 Apr 99. Posted 02/10/99 (A-SN296819). (0041)

Loren Data Corp. http://www.ld.com (SYN# 0286 19990212\65-0002.SOL)